Fresenius SE / Issue of Debt
Release of an Ad hoc announcement according to § 15 WpHG, transmitted by
DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
----------------------------------------------------------------------
Fresenius SE successfully executes offering of € 554 million mandatory
exchangeable bonds, exchangeable into ordinary shares of Fresenius Medical
Care
Fresenius SE today successfully priced an issue of mandatory exchangeable
bonds with an aggregate nominal amount of € 554.4 million. The bonds will
be issued by Fresenius Finance (Jersey) Ltd. Upon redemption the bonds will
be mandatorily exchangeable into ordinary shares of Fresenius Medical Care
AG & Co. KGaA.
The bonds have a maturity of 3 years. Upon maturity, a maximum of 16.80
million and a minimum of 14.24 million shares will be deliverable,
representing approximately 5.66 % and 4.80 %, respectively, of Fresenius
Medical Care’s total subscribed capital.
The bonds carry a coupon of 5.625 % p.a. The minimum exchange price equals
the reference share price of € 33.00 and the maximum exchange price has
been set 18 % above the reference share price. This structure allows
Fresenius SE to participate in a potential upside of Fresenius Medical Care
shares up to the maximum exchange price of € 38.94.
Settlement of the bonds is expected on August 14, 2008. Settlement of the
mandatory exchangeable bonds subscribed by Dr. Patrick Soon-Shiong, founder
and majority shareholder of APP Pharmaceuticals is subject to the closing
of Fresenius Kabi’s acquisition of APP Pharmaceuticals. Fresenius intends
to list the bonds in the Open Market (Freiverkehr) segment of the Frankfurt
Stock Exchange. However, the issue is not conditional upon obtaining
listing.
Credit Suisse, Deutsche Bank, Dresdner Kleinwort and JPMorgan acted as
Joint Bookrunners for the offering.
Concurrent with the issuance of the bonds a bookbuilding for an accelerated
secondary equity offering of Fresenius Medical Care shares has been carried
out by Credit Suisse and Deutsche Bank, without a direct involvement of
Fresenius SE. The concurrent equity offering is common market practice in
order to coordinate potential selling interest in Fresenius Medical Care
shares. The shares were placed at a price of € 33.00 per share.
Supplemental information to the Bond:
Issuer: Fresenius Finance (Jersey) Ltd
Shares: Fresenius Medical Care AG & Co. KGaA
ISIN: DE0005785802
WKN: 578580
Listed: Regulated Market / Prime Standard of the Frankfurt Stock
Exchange; New York Stock Exchange (NYSE)
The Management Board
Bad Homburg v.d.H., July 17, 2008
End of note
17.07.2008 Financial News transmitted by DGAP
----------------------------------------------------------------------
Language: English
Issuer: Fresenius SE
Else-Kröner-Straße 1
61352 Bad Homburg v.d.H.
Deutschland
Phone: +49 (0)6172 608-2485
Fax: +49 (0)6172 608-2488
E-mail: ir-fre@fresenius.com
Internet: www.fresenius.com
ISIN: DE0005785638, DE0005785604
WKN: 578563, 578560
Indices: MDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard), Düsseldorf,
München; Freiverkehr in Berlin, Hannover, Stuttgart, Hamburg;
Terminbörse EUREX
End of News DGAP News-Service
---------------------------------------------------------------------------